Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep biotech 1.png

The BioIndustry Association (BIA) today unveils its groundbreaking report, "Deep Biotech: Disruptive innovation for global sustainability", marking a defining moment in the UK’s science superpower ambitions. This comprehensive report not only sheds light on Deep Biotech's transformative potential but also positions the BIA as the leading voice representing innovative start-ups, scale-ups and established companies working in Deep Biotech. 

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

"We're not simply witnessing a biotech boom benefitting healthcare in the UK, the impact of this cutting-edge science runs much deeper" emphasises Steve Bates OBE, CEO of the BIA. "We're on the cusp of a biorevolution powered by Deep Biotech, and the BIA is at the forefront, as a key player in shaping the future of Deep Biotech and championing its disruptive potential." 

The BIA's Deep Biotech report serves as an invaluable new resource for companies and policymakers, delving into: 

  • The revolutionary power of Deep Biotech: Unlocking its transformative applications improving sustainability across various sectors, from energy and materials to food and the environment. 
  • Inspiring case studies:  Highlighting cutting-edge companies pioneering Deep Biotech solutions, from sustainable biofuels to lab-grown meat, including Moa Technology, Solena Materials, Phycobloom, Quest Meat and Epoch Biodesign. 
  • Challenges and opportunities: Addressing the regulatory, economic, and public acceptance hurdles Deep Biotech faces and outlining defining priorities and directions of its development to overcome them. 

 "This report is a call to action," declares Bates. "We invite policymakers, investors, and the public to join us in harnessing the immense power of Deep Biotech. Together, we can build a more sustainable, healthier future for generations to come." 

Andrew Griffith, UK Minister of State for Science, Research and Innovation, said: 

“Protecting our environment is one of the most significant challenges that we face today. This report highlights the promising solutions that biotech offers, from converting waste into useful fuel to replacing plastics with bio-based degradable materials. 

“The UK Government is backing our life sciences entrepreneurs who are working to make these solutions a reality, and through our engineering biology vision, we are supporting world-class research and development that will lead us to a more sustainable future.” 

The BIA is committed to nurturing the Deep Biotech ecosystem. Through thought leadership, advocacy, and industry events, the BIA will deliver new programmes of work in 2024 to empower Deep Biotech companies to thrive and scale, paving the way for a bio-powered future. 

Read the 'Deep Biotech: Disruptive innovation for global sustainability' report at deepbiotech.org  

 

Notes to Editors 

 

More news and updates 

Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner

Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science.

Resilient UK biotech sector lands £1.8 billion investment in 2023

New report highlights sector's strength, investor confidence and long-term returns. London-quoted biotechs also continue to outperform UK and US markets over the long term, having made substantial gains during the pandemic that have not been lost.   

BIA unveils new data: UK leads Europe in cell and gene therapy as sector makes significant strides  

The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.  

BIA reaches 600 member companies, announces new board and leadership restructure 

The UK’s innovative trade association for life science and biotech companies, BioIndustry Association (BIA), today announces that it has reached 600 companies in membership for the first time ever, alongside new Board and staff appointments for 2024.

BIA announces its Charity Partnership for 2024 with RNID

BIA is thrilled to announce its charity partnership of the year for 2024 with RNID, the national charity supporting the 12 million people in the UK who are deaf, have hearing loss or tinnitus. 

BIA responds to the Chancellor's Autumn Statement 2023

Life science spin-outs, start-ups and scale-ups are key drivers of the UK’s innovation-based economy and crucial for discovering and developing new medicines to save lives in the NHS. The UK is home to a third of life science startups founded in Europe since 2012 and companies like them are responsible for nearly two-thirds of medicines being developed globally.

bioProcessUK to celebrate biotech’s shining stars 

The BioIndustry Association (BIA) will honour two distinguished individuals for their exceptional contributions to the innovative life sciences and biotech sector.

UK biotech fundraising picks up with best quarterly total since 2021

The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.

Rare disease companies call for UK leadership in supporting access to new treatments

A group of companies developing innovative new medicines for rare diseases, working together through their trade association, is calling for the UK to lead greater collaboration between stakeholders, and uptake of best practice both in the UK and internationally, to improve access to new treatments for patients.

 

More within